PINP as a biological response marker during teriparatide treatment for osteoporosis - Wikidata - awgldk - TriplyDB

PINP as a biological response marker during teriparatide treatment for osteoporosis

PINP as a biological response marker during teriparatide treatment for osteoporosis

http://www.wikidata.org/entity/Q26859267

about

Teriparatide for osteoporosis: importance of the full course Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy.Chronic kidney disease and osteoporosis: evaluation and management.Chronic kidney disease and the skeleton.Teriparatide improves volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone failure type PJK after surgery for adult spinal deformity.Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.Necrostatin-1 treatment inhibits osteocyte necroptosis and trabecular deterioration in ovariectomized rats.The Utility of Biomarkers in Osteoporosis Management.Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study.Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: A pilot study.Anabolic treatment for osteoporosis: teriparatide.Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans.A retrospective analysis of nonresponse to daily teriparatide treatment.Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates.Influence of Apelin-13 on osteoporosis in Type-2 diabetes mellitus: A clinical study.Bone Turnover Status: Classification Model and Clinical Implications.Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management

P2860

Q26768410-EFD09514-C88C-4F83-8C93-D5BEC1F68F7C Q33607092-4A4E4CCB-2A1B-4D09-928B-68158B1FEAC4 Q33792658-55397683-1988-4CB4-9DFC-66F29B0633F5 Q33833414-3533898D-70BD-40C5-9AD5-3819A57E346B Q35755179-66D05CF4-9497-45B2-B347-0ED45D4365EA Q36061231-D77C4019-AEBE-4AD5-BE2D-C26FC2FD35FB Q37082771-75CA8831-E6BC-41C8-8AE7-D658B6D266B8 Q37310688-BF6A5183-078F-49A7-9C76-A1FC88A880A1 Q38921875-298CE1C0-D047-406E-9461-BB7152DE2571 Q42688220-78A053A5-7E83-4814-A5F1-355529DBEB88 Q42688632-61BB34C4-3729-4D52-B984-CCCFE122F144 Q47163541-8D526E6C-BE09-4C15-BA13-8962C764F8D4 Q47668375-5E5551E3-EA9A-4F4D-843A-E14D79EBA19B Q50911376-7A45C614-6303-431E-9002-ECA96BD2AE29 Q50960182-CB5777FC-C859-4693-8AAB-431DE5353B5E Q54940887-82FEACED-1CA3-4607-9F38-CC0ACD48E5E5 Q55002406-55F0BA55-FDFD-48ED-9F05-CE3EBEB177F4 Q57213305-2EED068E-9C8C-4257-B5A9-5E6941A68C19 Q57494538-867D7B17-CCCA-4DDD-9728-5118E1CEC13A Q59051207-1C11C5F3-38B6-453A-9BBF-3636E2F3D70A

P2860

PINP as a biological response marker during teriparatide treatment for osteoporosis

http://www.wikidata.org/entity/Q26859267

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PINP as a biological response marker during teriparatide treatment for osteoporosis

@ast

PINP as a biological response marker during teriparatide treatment for osteoporosis

@en

PINP as a biological response marker during teriparatide treatment for osteoporosis

@nl

type

label

PINP as a biological response marker during teriparatide treatment for osteoporosis

@ast

PINP as a biological response marker during teriparatide treatment for osteoporosis

@en

PINP as a biological response marker during teriparatide treatment for osteoporosis

@nl

prefLabel

PINP as a biological response marker during teriparatide treatment for osteoporosis

@ast

PINP as a biological response marker during teriparatide treatment for osteoporosis

@en

PINP as a biological response marker during teriparatide treatment for osteoporosis

@nl

P1433

Q26859267-62DC314D-0795-4440-85A5-09C2530659AC

P1476

Q26859267-C321CB25-BF43-42A7-989D-946F14949B6B

P2093

Q26859267-4F8BDE50-DDEB-41F3-8BFA-79AAF4098E90

Q26859267-86728816-2F84-40D7-A80B-2D3E99D86316

Q26859267-E3349AF8-A446-4ED4-AC55-93D2F9E6183B

Q26859267-E38D40DA-4B09-4B6F-803E-53BBFD50B921

P2860

Q26859267-006016F8-2564-46D4-A234-A695F286A70F

Q26859267-09D27695-289B-4A76-B006-584D454AE470

Q26859267-0A52FD21-BCC5-4457-BCC3-78E3E3E8E764

Q26859267-12EFD770-E429-49B3-83FE-F5BEA5C2F805

Q26859267-1395BC15-F634-4FAF-8C30-B1E8740534EE

Q26859267-29E2BEB7-5F50-46E5-BC38-D6A04AC365AD

Q26859267-2CB057F3-5A15-47B3-8767-E02B91826DBA

Q26859267-31FE2EE8-CEE2-40EA-9880-7184846DE245

Q26859267-35DC37DC-65DC-4F00-B914-B35012BD499D

Q26859267-4C872CAC-1664-4334-9BE8-C131C17865D6

P2888

Q26859267-C025DBAF-F837-4DCB-9606-AF2F2D09CC08

P304

Q26859267-B44B78E6-6830-449C-9273-DC89070AFDCD

P31

Q26859267-A059E20B-8714-46AB-88A0-07FF79FFBF2D

Q26859267-BBF811BC-1969-4941-A036-44D133972ED2

P3181

Q26859267-DF042C1C-0527-4CB4-B21D-4787395EEDEC

P356

Q26859267-FD8694CA-0F03-4A16-939A-2BE78AEFD798

P407

Q26859267-DF260620-F063-4EEC-AFDE-51BD251FD17B

P433

Q26859267-D0DF0EF9-3C2B-41AE-918B-6337E23AEDAA

P478

Q26859267-1742636A-D7B8-4B3A-8EC3-0D1AB363FFB1

P577

Q26859267-7BB1C420-87ED-4551-B9B4-9A532484EFBA

Q26859267-7D28B73E-06EF-4008-B2B1-597100B51E82

P5875

Q26859267-47F3CCFD-DCAD-459A-AEF4-3A61A6C5842D

P6179

Q26859267-968C0EBE-474B-48A3-9AF1-134303448E94

P698

Q26859267-8B52AA9E-943E-4BD2-B161-DB7F4DD2DBA2

P921

Q26859267-004E0446-A020-439A-AEC9-A0182FE0F3BC

Q26859267-31F2CECF-FBE1-4D37-BB3A-7E9214046317

Q26859267-55F86DF9-0F95-4AA5-BC13-423B729994BA

Q26859267-C05F6098-9AFA-4ADA-926C-6622F90AF40D

Q26859267-C0D04F56-FFFA-4C56-B28C-622E01ABB3DA

Q26859267-CE5B8BA2-8C82-4BFC-B107-8565F64CF4E0

P932

Q26859267-3468A9D4-F9CC-4E24-B324-2F9864015DDE

P3181

P356

S00198-014-2646-0

P1433

Osteoporosis International

P1476

PINP as a biological response marker during teriparatide treatment for osteoporosis

@en

P2093

J. H. Krege

http://www.w3.org/2001/XMLSchema#string

J. M. Harris

http://www.w3.org/2001/XMLSchema#string

N. E. Lane

http://www.w3.org/2001/XMLSchema#string

P. D. Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

Immunoassay for intact amino-terminal propeptide of human type I procollagen.

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

Biochemical markers in the follow-up of the osteoporotic patients.

P2888

s00198-014-2646-0

P304

2159-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3141376

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00198-014-2646-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260557085

http://www.w3.org/2001/XMLSchema#string

P6179

1013749284

http://www.w3.org/2001/XMLSchema#string

P698

24599274

http://www.w3.org/2001/XMLSchema#string

P921

fibrous protein

protein precursor

postmenopausal osteoporosis

P932

4134485

http://www.w3.org/2001/XMLSchema#string